Sangamo Announces Second Expansion of Research Collaboration with LifeScan
News Sep 15, 2005
Sangamo BioSciences, Inc. has announced the second expansion of its research collaboration with LifeScan, Inc. to use Sangamo's proprietary zinc finger DNA binding proteins (ZFPs) to develop therapeutic cell lines as a treatment for diabetes.
Under the agreement, Sangamo will receive expanded research funding from LifeScan through 2006.
"Our research collaboration with LifeScan illustrates the potential of our ZFP technology to play a key role in regenerative medicine approaches," said Edward Lanphier, Sangamo's president and chief executive officer.
"We can design and engineer ZFP transcription factors (ZFP TFs) that specifically regulate the expression of genes that LifeScan has identified as critical for the development of potential cell therapeutics for the treatment of diabetes.”
“Our initial collaboration has gone very well and we believe that LifeScan's decision to extend our agreement demonstrates their enthusiasm for our technology and its potential for developing novel therapeutics."
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE